ProQR Therapeutics Submits CTA for AX-0810 Phase 1 Study
Ticker: PRQR · Form: 6-K · Filed: Jun 26, 2025 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, regulatory-filing
TL;DR
ProQR just filed for a Phase 1 study of AX-0810 targeting NTCP. Big step for their liver disease drug.
AI Summary
On June 26, 2025, ProQR Therapeutics N.V. announced the submission of a Clinical Trial Application (CTA) for a Phase 1 study of its investigational drug AX-0810. This drug is designed to target NTCP, a protein involved in certain liver diseases. The submission marks a significant step in the development of AX-0810.
Why It Matters
This filing indicates ProQR Therapeutics is advancing its pipeline, potentially bringing a new treatment option for liver diseases closer to patients.
Risk Assessment
Risk Level: medium — Clinical trial submissions are early-stage and carry inherent risks of failure in subsequent development phases.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer of the 6-K report and developer of AX-0810
- AX-0810 (drug) — Investigational drug targeting NTCP
- NTCP (target) — Protein targeted by AX-0810
- June 26, 2025 (date) — Date of the press release and CTA submission announcement
FAQ
What is the specific indication ProQR Therapeutics is targeting with AX-0810?
The filing states AX-0810 targets NTCP, which is involved in certain liver diseases, but does not specify the exact indication in this announcement.
When was the Clinical Trial Application (CTA) submitted?
The press release announcing the CTA submission was issued on June 26, 2025.
What is the planned phase for the study of AX-0810?
The planned phase for the study of AX-0810 is Phase 1.
What is the ticker symbol for ProQR Therapeutics N.V.?
The filing does not explicitly state the ticker symbol, but the SEC file number is 001-36622.
Where is ProQR Therapeutics N.V. headquartered?
ProQR Therapeutics N.V. is headquartered in Leiden, The Netherlands.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 26, 2025 regarding ProQR Therapeutics N.V. (PRQR).